No Transplant, No Problem: Redefining First-Line Myeloma Care With Anti

Ajai Chari, M.D., is the director of the multiple myeloma program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center. In this Managed Healthcare Executive K-Cast video series, Chari reviewed the evolution of first-line therapy for patients with transplant-ineligible myeloma, clinical trials comparing triplet (three-drug) therapy to quadruplet (four-drug) therapy and the role of anti-CD38 therapies, two of which have been approved by the FDA: daratumumab (sold under the brand name Darzalex) and isatuximab (sold under the brand name Sarclisa).

From doublet to triplet

Many patients with myeloma receive stem cell transplants. Still, patients who are older or have other health problems may not be eligible for transplants, and the treatment choice